Designed as a ‘GPS’ to Multiply the Efficacy, Safety & Affordability of Blood, Cell & Gene Therapies
TZ 101 is our phase 3 ready, off-the-shelf medical kit comprised of fucosyltransferase enzyme VI and a small molecule product. Its purpose is to prevent and reduce the risks of various life-threatening side effects associated with standard-of-care therapies. These side effects include serious viral, bacterial, and fungal infections, graft-versus-host disease, hemorrhaging, and stem cell engraftment failure. The product has been awarded an FDA Phase 3 Special Protocol Assessment, which provides a clear regulatory pathway for FDA marketing approval.
Remarkable Phase 2 clinical results at MD Anderson Cancer Center showed that TZ 101 Treated Mononuclear Cells (Stem Cells, T-cells, B Cells, NK Cells, Tregs etc) in Phase 2 Trial Led to:
- 29-31% Acceleration of Hematopoietic Recovery
- 61-84% Reduced Incidence of Bacterial, Fungal, Viral Infections
- 82% Reduction in T-Cells Attacking Various Organs (cGVHD)
- Product is Safe in Humans with no adverse events attributed to TZ 101
This user-friendly medical kit can be easily administered at the patient’s bedside in a cancer center, along with peripheral blood or marrow transfusions. It provides immediate potentially preventive care treatment for terminally ill cancer patients, as well as those with auto-immune and blood diseases who are undergoing standard-of-care cancer therapies such as intense chemotherapy and hematopoietic stem cell transplantation.
In contrast to alternative cell expansion and genetic engineering products, TZ 101 enables immediate and more affordable patient treatment. It eliminates the need for patients to endure weeks of disease progression before receiving treatment. The simplified steps for administering TZ 101 are outlined below.
By potentially preventing and reducing the risks of multiple serious side effects associated with standard-of-care toxic therapies, TZ 101 may help reduce the need for patients to receive numerous supportive care drugs, often exceeding 10 or 20, each treating a single morbidity along with their associated costs and side effects. This would enable patients to live longer with a better quality of life while reducing the overall cost of curative therapies.
Please click below to see our pipeline.
Learn More